

CENTRAL FAX CENTER

JUL 14 2004

OFFICIAL

FAX TRANSMISSION

DATE: July 14, 2004

PTO IDENTIFIER: Application Number 10/777,043
Patent Number

Inventor: Eliezer Rapaport

MESSAGE TO: US Patent and Trademark Office

FAX NUMBER: (703) 872-9306

FROM: CONNOLLY BOVE LODGE & HUTZ LLP

Burton A. Amernick

PHONE: (202) 331-7111

Attorney Dkt. #: 21095-00008-US1

PAGES (Including Cover Sheet): 6

CONTENTS: Information Disclosure Statement (2 pages);
IDS (Citations) by Applicant (2 pages); and
Certificate of Transmission under 37 CFR 1.8 (1 page).

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (202) 331-7111 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

CONNOLLY BOVE LODGE & HUTZ LLP
1990 M Street, N.W., Suite 800, Washington, DC 20036-3425
Telephone: (202) 331-7111 Facsimile: (202) 293-8229

PTO/SB/97 (12-97)

Approved for use through 9/30/00. OMB 0851-0031


Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.~~

Certificate of Transmission Under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on July 14, 2004
Date


Signature

Debra Bennett
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Information Disclosure Statement (2 pages);
IDS (Citations) by Applicant (2 pages); and
Certificate of Transmission under 37 CFR 1.8 (1 page).

RECEIVED
CENTRAL FAX CENTER

JUL 14 2004

Docket No.: 21095-00008-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Eliezer Rapaport

Application No.: 10/777,043

Confirmation No.: 3919

Filed: February 13, 2004

Art Unit: 1623

For: METHODS, PHARMACEUTICAL AND
THERAPEUTIC COMPOSITIONS FOR
ADMINISTERING ADENOSINE

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Copies of the references on the PTO/SB/08 are not provided. Copies of references AA and AB are not required. Copies of references CA-CW can be found in the file of parent application S.N. 10/111,167 filed April 22, 2002.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information


as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any required fees to Deposit Account 22-0185.

Dated:

Respectfully submitted,

By 

Burton A. Amernick

Registration No.: 24,852

CONNOLLY BOVE LODGE & HUTZ LLP

1990 M Street, N.W., Suite 800

Washington, DC 20036-3425

(202) 331-7111

(202) 293-6229 (Fax)

Attorney for Applicant

PTO/SB/08a/b (09-03)

Approved for use through 07/31/2005. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/777,043		
		Filing Date	February 13, 2004		
		First Named Inventor	Eliezer Rapaport		
		Art Unit	1623		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	2	Attorney Docket Number	21095-00008-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,900,407-A1	05-04-1999	YERXA et al.	
	AB	US-5,017,564	05-1991	Makino et al	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	VOET et al., Fundamentals of Biochemistry, John Wiley & Sons, Inc., 1999, p. 44.	
	CB	Remington's Pharmaceutical Sciences, Fifteenth Edition, 1975, pp. 1587 and 1614-1615.	
	CC	Paul J. ARCIERO et al., AGE and NE and FFA Kinetics After Caffeine Ingestion, pp. E1192-E1198, Effects of Caffeine Ingestion on NE Kinetics, Fat Oxidation, and Energy Expenditure in Younger and Older Men.	
	CD	G. BURNSTOCK, Part 1. Biological Effects of Extracellular ATP and Nucleotides, pp. 1-17, Purinergic Mechanisms.	
	CE	Council on Scientific Affairs, Council Report, JAMA, 1988, vol. 260, No. 17, pp. 2547-2551, Treatment of Obesity in Adults.	
	CF	HOPPE et al., 16. Desensitization of A1 Adenosine Receptors, pp. 133-138.	
	CG	Kenneth A. JACOBSON et al., Purinergic Approaches in Experimental Therapeutics, 1997, pp. 102-129, Development of Selective Purinoceptor Agonists and Antagonists.	
	CH	Kollias-BAKER et al., 26. Myocardial Adenosine Receptors, pp. 221-228.	
	CI	Kathryn La NOUE et al., The FASEB Journal, 1994, vol. 8, pp. 72-80, Abnormal A1 Adenosine Receptor Function in Genetic Obesity.	
	CJ	H. Thomas LEE et al., The American Physiological Society, 1993, pp. H1916-H1927, Cardiac Desensitization to Adenosine Analogues After Prolonged R-PIA Infusion in Vivo.	
	CK	Joel LINDEN, The FASEB Journal, 1991, vol. 5 pp. 2668-2676, Structure and Function A1 Adenosine Receptors.	
	CL	Joel LINDEN, Purinergic Approaches in Experimental Therapeutics, 1997, pp. 84-97, Allosteric Enhancement of Adenosine Receptors.	
	CM	Khalid A. MOHAMEDALI et al., The Journal of Biological Chemistry, 1993, vol. 268., No. 31, pp. 23728-23733, The Highest Levels of Purine Catabolic Enzymes in Mice are Present in the Proximal Small Intestine.	
	CN	Eliezer RAPAPORT, Department of Microbiology, pp. 142-149, Mechanisms of Anticancer Activities of Adenine Nucleotides in Tumor-Bearing Hosts.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

PTO/SB/08a/b (09-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
		Application Number	10/777,043
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	February 13, 2004
		First Named Inventor	Eliezer Rapaport
		Art Unit	1623
		Examiner Name	Not Yet Assigned
Sheet	2	of	2
		Attorney Docket Number	21095-00008-US1

CO	Eliezer RAPAPORT et al., Proc. Natl. Acad. Sci. USA, 1976, vol. 73, No. 9, pp. 3122-3125, Incorporation of Adenosine Into ATP: Formation of Compartmentalized ATP.
CP	Eliezer RAPAPORT et al., Biochemical Pharmacology, 1989, vol. 38 No. 23 pp. 4261-4266, Generation of Extracellular ATP in Blood and its Mediated Inhibition of Host Weight Loss in Tumor-Bearing Mice.
CQ	Eliezer Rapaport et al., Proc. Natl. Acad. Sci., 1989, vol. 86, pp. 1662-1666, Anticancer Activities of Adenine Nucleotides In Mice Are Mediated Through Expansion of Erythrocyte ATP Pools.
CR	John SHRYOCK et al., The American Physiological Society, 1989, pp. H321-H327, Downregulation And Desensitization of A1-Adenosine Receptors in Embryonic Chicken Heart.
CS	Linda L. SLAKEY et al., Part V. Metabolism and Utilization of Extracellular ATP by Ectoenzymes, pp. 366-379, A Comparison of Ectonucleotidase Activities On Vascular Endothelial and Smooth Muscle Cells.
CT	PH. Van Der GRAFF et al., The Journal of Pharmacology and Experimental Therapeutics, 1999, vol. 290, No.2, pp.702-709, Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Antilipolytic Effects of Adenosine A1 Receptor Agonists in Rats: Prediction of Tissue-Dependent Efficacy in Vivo.
CU	E.A. Van SCHAICK et al., The Journal Of Pharmacology and Experimental Therapeutics, 1998, vol. 287, No. 1, pp. 21-30, Metabolic And Cardiovascular Effects of The Adenosine A1 Receptor Agonis N6-(p-Sulfophenyl) Adenosine in Diabetic Zucker Rats: Influence of the Disease on the Selectivity of Action.
CV	Michael WILLIAMS et al., Purinergic Approaches in Experimental Therapeutics, 1997, pp. 3-26, Purinergic Neurotransmission and Neuromodulation a Historical Perspective.
CW	Baiyand XU et al., The American Physiological Society, 1998, pp. E271-E279, A1 Adenosine Receptor Antagonism Improves Glucose Tolerance In Zucker Rats.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--